And the firm filed the nation’s first legal action alleging that the drug’s recommended once-a-day dosage doesn’t work for as long as promised, sometimes with life-threatening results.
Ross Feller Casey filed that lawsuit in Philadelphia on behalf of a Florida man who suffered an ischemic stroke because the drug didn’t work for as long as the manufacturer suggested. The firm, which is at the forefront of this legal theory, is preparing to file numerous other suits shortly on behalf of clients from across the country with similar claims.
Xarelto does not prevent, and may actually have contributed to, ischemic strokes in clients suffering from atrial fibrillation. The drug’s indicated 20mg dose results in a lack of protection against stroke/systemic embolism for a substantial portion of the day if the dose is given once daily, the suit alleges.
Xarelto is the only new anticoagulant recommended by the manufacturer for once-per-day dosing in the clinical setting of non-valvular atrial fibrillation. All other comparable anticoagulants are dosed on a twice-per-day basis.
Xarelto (rivaroxaban) is an oral anti-clotting medication or “blood thinner,” which is prescribed to prevent and to treat deep vein thrombosis (blood clots in the legs) and pulmonary embolism (blood clots to the lungs). It also is used to reduce the risk of stroke in some patients with a common heart arrhythmia known as atrial fibrillation. It may also be prescribed to patients undergoing knee or hip replacement surgery to prevent clots from forming in the legs and traveling to the lungs.
The FDA approved Xarelto to reduce the risk of deep vein thrombosis and pulmonary embolism in July 2011. The FDA then expanded its approval to the ongoing treatment and prevention of deep vein thrombosis and pulmonary embolism in November 2012. The FDA also approved Xarelto for reduction of stroke risk in certain patients with atrial fibrillation in November 2011.
Xarelto is manufactured by Johnson & Johnson’s Janssen Pharmaceuticals and Bayer. In 2013, the institute for Safe Medication’s Practice QuarterWatch reported a steady increase in adverse events reported to the FDA for Xarelto.
In January 2014, the FDA’s safety surveillance agency announced a plan to monitor and study Xarelto for serious events such as ischemic strokes, intracranial hemorrhages, and gastrointestinal bleeding. There is currently no reversal agent for Xarelto.
Injuries that can occur when using Xarelto include:
- Gastrointestinal bleeding
- Cerebral hemorrhage
- Uncontrolled hemorrhage
- Internal bleeding
Signs and symptoms of a Xarelto injury may include:
- Stroke (bleeding into the brain)
- Unusual bleeding
- Discolored urine (blood in the urine)
- Red or black-colored stool (blood in bowel movements)
- Coughing up blood
- Vomiting blood that looks like “coffee grounds” or is bright red
- Frequent nose bleed or gum bleeding
- Weakness and swelling in the extremities
- Neurological injury (bleeding around spinal cord)
Are you wondering: How do I find a Xarelto lawyer near me?
If you or a loved one has suffered a stroke or other severe injuries while taking Xarelto, you should contact a pharmaceutical injury lawyer at Ross Feller Casey immediately for a free case evaluation. You may be entitled to compensation by filing a Xarelto lawsuit, and we can help.
Ross Feller Casey has a team of leading, nationally recognized doctors right on staff to immediately evaluate your Xarelto case.
In fact, Ross Feller Casey’s Mark A. Hoffman, M.D. was recently appointed by a federal judge to serve on the national Plaintiffs Steering Committee for Xarelto lawsuits. By virtue of that role, Ross Feller Casey will help shape all Xarelto lawsuits as they progress through the court.
We are handling individual litigation nationwide, and our Xarelto lawyers are currently accepting new stroke related and internal bleeding cases in all 50 states.
Ross Feller Casey handles cases, including Xarelto lawsuits, on a contingency basis, so you will not pay anything unless we recover compensation on your behalf.